(±)5(6)-DiHET
(Synonyms: (±)5,6-DiHETrE) 目录号 : GC40270A racemic version of a CYP450 pathway metabolite of arachidonic acid
Cas No.:213382-49-1
Sample solution is provided at 25 µL, 10mM.
5(6)-DiHET is a fully racemic version of the enantiomeric forms biosynthesized from 5(6)-EET by epoxide hydrolases. [1] 5(6)-DiHET can be used to quantify 5(6)-EET due to the conversion of 5(6)-EET to 5(6)-δ-lactone in solution. [2] 5(6)-DiHET activates large conductance calcium-activated potassium (BK) channels in smooth muscle cells from rat small coronary arteries. [3 It is a substrate for sheep seminal vesicle COX, producing 5,6-dihydroxy prostaglandin E1 and F1α metabolites in vitro. [4] 5(6)-DiHET levels decrease in plasma in a high-fat diet-induced rat model of hyperlipidemia.[5]
Reference:
[1]. Oliw, E.H., Guengerich, F.P., and Oates, J.A. Oxygenation of arachidonic acid by hepatic monooxygenases. Isolation and metabolism of four epoxide intermediates. J. Biol. Chem. 257(7), 3771-3781 (1982).
[2]. Rashid, M., Manivet, P., Nishio, H., et al. Identification of the binding sites and selectivity of sarpogrelate, a novel 5-HT2 antagonist, to human 5-HT2A, 5-HT2B and 5-HT2C receptor subtypes by molecular modeling. Life Sci. 73(2), 193-207 (2003).
[3]. Lu, T., Katakam, P.V.G., VanRollins, M., et al. Dihydroxyeicosatrienoic acids are potent activators of Ca2+-activated K+ channels in isolated rat coronary arterial myocytes. J. Physiol. 534(Pt 3), 651-667 (2001).
[4]. Oliw, E.H. Biosynthesis of 5,6-dihydroxyprostaglandin E1 and F1α from 5,6-dihydroxyeicosatrienoic acid by ram seminal vesicles. Biochim. Biophys. Acta. 795(2), 384-391 (1984).
[5]. Miao, H., Zhao, Y.-H., Vaziri, N.D., et al. Lipidomics biomarkers of diet-induced hyperlipidemia and its treatment with Poria cocos. J. Agric. Food Chem. 64(4), 969-979 (2016).
Cas No. | 213382-49-1 | SDF | |
别名 | (±)5,6-DiHETrE | ||
化学名 | (±)5,6-dihydroxy-8Z,11Z,14Z-eicosatrienoic acid | ||
Canonical SMILES | CCCCC/C=C\C/C=C\C/C=C\C[C@@H](O)[C@@H](O)CCCC(O)=O | ||
分子式 | C20H34O4 | 分子量 | 338.5 |
溶解度 | 50mg/mL in DMSO, 50mg/mL in DMF | 储存条件 | Store at -20°C |
General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 储备液的保存方式和期限:-80°C 储存时,请在 6 个月内使用,-20°C 储存时,请在 1 个月内使用。 为了提高溶解度,请将管子加热至37℃,然后在超声波浴中震荡一段时间。 |
||
Shipping Condition | 评估样品解决方案:配备蓝冰进行发货。所有其他可用尺寸:配备RT,或根据请求配备蓝冰。 |
制备储备液 | |||
1 mg | 5 mg | 10 mg | |
1 mM | 2.9542 mL | 14.771 mL | 29.5421 mL |
5 mM | 0.5908 mL | 2.9542 mL | 5.9084 mL |
10 mM | 0.2954 mL | 1.4771 mL | 2.9542 mL |
第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量) | ||||||||||
给药剂量 | mg/kg | 动物平均体重 | g | 每只动物给药体积 | ul | 动物数量 | 只 | |||
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系GLPBIO为您提供正确的澄清溶液配方) | ||||||||||
% DMSO % % Tween 80 % saline | ||||||||||
计算重置 |
计算结果:
工作液浓度: mg/ml;
DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,
体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL saline,混匀澄清。
1. 首先保证母液是澄清的;
2.
一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch:
- Purity: >95.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet